Screener / SEC EDGAR /CIK 0001717115 /10-K filed Feb 24, 2026, compared with Feb 24, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Technology · Internet & Software Services

Tempus AI, Inc. TEM

Compare with peers Embed
Why it changed

The biggest changes in the 10-K filed Feb 24, 2026, in management's words

10-K, Item 7

This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.

Operating margin

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

-99.7% to -19.9% (+79.8 pts)

“The decrease in Technology research and development expenses for the year ended December 31, 2025, compared to the same period in 2024, was primarily due to a decrease of $39.4 million of stock-based compensation expenses related to RSUs for which the performance-based vesting condition was satisfied in connection with our IPO in the prior period, offset by an increase of $19.5 million in personnel-related costs associated with the investment in our cloud infrastructure and new lines of business, of which $13.0 million is due to the Ambry Acquisition.”

Read it in the 10-K

Revenue

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

+83.4%

“The increase in revenue for the year ended December 31, 2025, compared to the same period in 2024, was due to increased volume and reimbursement of clinical oncology and hereditary tests performed in Diagnostics and increased data deliveries in our Data and applications product line.”

Read it in the 10-K

“The increase in Diagnostics revenue for the year ended December 31, 2025, compared to the same period in 2024, was primarily due to an increase in the number of Oncology tests and the addition of Hereditary tests through the acquisition of Ambry.”

Read it in the 10-K

What management said, year by year

The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)

Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.

Revenue

2 of 2 years explained
  • FY 2025 +83.4%

    “The increase in revenue for the year ended December 31, 2025, compared to the same period in 2024, was due to increased volume and reimbursement of clinical oncology and hereditary tests performed in Diagnostics and increased data deliveries in our Data and applications product line.”

    Read it in the FY 2025 10-K

    “The increase in Diagnostics revenue for the year ended December 31, 2025, compared to the same period in 2024, was primarily due to an increase in the number of Oncology tests and the addition of Hereditary tests through the acquisition of Ambry.”

    Read it in the FY 2025 10-K
  • FY 2024 +30.4%

    “The increase in revenue for the year ended December 31, 2024, compared to the same period in 2023, was due to increased volume and reimbursement of clinical oncology tests performed in Genomics and increased data deliveries in our Data and Services product line.”

    Read it in the FY 2024 10-K

    “The increase in Genomics revenue for the year ended December 31, 2024, compared to the same period in 2023, was primarily due to an increase in the number of oncology NGS tests, which increased from approximately 218,700 tests for the year ended December 31, 2023 to approximately 270,800 tests for the year ended December 31, 2024.”

    Read it in the FY 2024 10-K

Operating margin

2 of 2 years explained
  • FY 2025 +79.8 pts

    “The decrease in Technology research and development expenses for the year ended December 31, 2025, compared to the same period in 2024, was primarily due to a decrease of $39.4 million of stock-based compensation expenses related to RSUs for which the performance-based vesting condition was satisfied in connection with our IPO in the prior period, offset by an increase of $19.5 million in personnel-related costs associated with the investment in our cloud infrastructure and new lines of business, of which $13.0 million is due to the Ambry Acquisition.”

    Read it in the FY 2025 10-K
  • FY 2024 -62.8 pts

    “The increase in Technology research and development expenses for the year ended December 31, 2024, compared to the same period in 2023, was primarily due to an increase of $58.5 million of stock-based compensation expenses related to RSUs for which the performance-based vesting condition was satisfied in connection with our IPO, $11.1 million in personnel-related costs associated with the investment in our cloud infrastructure and new lines of business, and $2.7 million in taxes related to the settlement of RSUs.”

    Read it in the FY 2024 10-K

    “The increase in Research and development expenses for the year ended December 31, 2024, compared to the same period in 2023, was primarily due to an increase of $47.6 million of stock-based compensation expenses related to RSUs for which the performance-based vesting condition was satisfied in connection with our IPO, $5.7 million in personnel-related costs for employees in our research and development group, $1.8 million in third party sequencing fees, and $1.8 million in validation and regulatory fees.”

    Read it in the FY 2024 10-K

Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K

Sources

The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.

Also

Financials: the numbers year by year.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TEM/export.csv") into a cell.

Next:Accounting checks
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.